The Future of Gene Editing with Programmable Recombinases

Before CRISPR-based methods took center stage in the genome editing field, other bio-inspired tools such as zinc finger nucleases and Cre-lox system recombinases made genomic engineering possible. Some researchers are now looking back to these foundational technologies to improve upon and one-up the latest gene editing techniques.

In this episode of The Scientist Speaks, Deanna MacNeil spoke with Frank Buchholz, professor and head of the medical systems biology translational research group at the Technical University of Dresden’s University Cancer Center, to explore how his laboratory designs programmable recombinases for high fidelity gene editing.

More on this topic: CRISPR Therapy Progress and Prospects

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services Team. Our podcast is by scientists and for scientists. We bring you the stories behind news-worthy molecular biology research. This month’s episode is sponsored by Oxford Nanopore.

Speaker:

Frank Buchholz, PhD
Professor, Medical Systems Biology
Head of Translational Research
University Cancer Center
Technical University Dresden

Oxford Nanopore offers industry-leading sequencing solutions across the whole spectrum of biopharmaceutical R&D—from initial target identification and biomarker discovery to cell line and viral vector engineering, all the way through to cell, gene, and RNA therapy drug development.